Debjit Chattopadhyay
Stock Analyst at Guggenheim
Total Price Targets
18
Stocks Covered
17
Sectors
Healthcare
Most Recent
Feb 18, 2026
Notable Calls (Last 12 Months)
Most Bullish
Stocks Covered by Debjit Chattopadhyay
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| PEPG | PepGen Inc. | $7.00 | $1.74 | +303.5% | 1 | Feb 18, 2026 |
| MAZE | Maze Therapeutics, Inc. | $46.00 | $27.23 | +68.9% | 2 | Dec 19, 2025 |
| PHVS | Pharvaris N.V. | $39.00 | $29.04 | +34.3% | 1 | Dec 4, 2025 |
| KRYS | Krystal Biotech, Inc. | $224.00 | $265.25 | -15.6% | 1 | Oct 17, 2025 |
| NTLA | Intellia Therapeutics, Inc. | $14.00 | $13.20 | +6.1% | 1 | Aug 13, 2025 |
| BEAM | Beam Therapeutics Inc. | $55.00 | $31.02 | +77.3% | 1 | May 7, 2025 |
| SLNO | Soleno Therapeutics, Inc. | $81.00 | $52.86 | +53.2% | 1 | Mar 28, 2025 |
| IONS | Ionis Pharmaceuticals, Inc. | $65.00 | $75.86 | -14.3% | 1 | Oct 9, 2024 |
| STOK | Stoke Therapeutics, Inc. | $35.00 | $33.22 | +5.4% | 1 | Sep 11, 2024 |
| RZLT | Rezolute, Inc. | $5.50 | $3.31 | +66.4% | 1 | Aug 27, 2024 |
| ALLO | Allogene Therapeutics, Inc. | $9.00 | $2.15 | +319.6% | 1 | May 16, 2024 |
| FATE | Fate Therapeutics, Inc. | $5.00 | $1.55 | +221.5% | 1 | May 16, 2024 |
| FOLD | Amicus Therapeutics, Inc. | $13.00 | $14.49 | -10.3% | 1 | May 14, 2024 |
| MGNX | MacroGenics, Inc. | $4.00 | $3.16 | +26.6% | 1 | May 13, 2024 |
| ALNY | Alnylam Pharmaceuticals, Inc. | $170.00 | $297.62 | -42.9% | 1 | Feb 3, 2022 |
| VRTX | Vertex Pharmaceuticals Incorporated | $286.00 | $425.06 | -32.7% | 1 | Dec 1, 2021 |
| BMRN | BioMarin Pharmaceutical Inc. | $120.00 | $54.20 | +121.4% | 1 | Nov 19, 2021 |
Recent Activity
- Feb 18, 2026— Set$7.00price target onPEPG(PepGen Inc.)
- Dec 19, 2025— Set$46.00price target onMAZE(Maze Therapeutics, Inc.)
- Dec 4, 2025— Set$39.00price target onPHVS(Pharvaris N.V.)
- Oct 17, 2025— Set$224.00price target onKRYS(Krystal Biotech, Inc.)
- Sep 15, 2025— Set$34.00price target onMAZE(Maze Therapeutics, Inc.)
- Aug 13, 2025— Set$14.00price target onNTLA(Intellia Therapeutics, Inc.)
- May 7, 2025— Set$55.00price target onBEAM(Beam Therapeutics Inc.)
- Mar 28, 2025— Set$81.00price target onSLNO(Soleno Therapeutics, Inc.)
- Oct 9, 2024— Set$65.00price target onIONS(Ionis Pharmaceuticals, Inc.)
- Sep 11, 2024— Set$35.00price target onSTOK(Stoke Therapeutics, Inc.)
- Aug 27, 2024— Set$5.50price target onRZLT(Rezolute, Inc.)
- May 16, 2024— Set$9.00price target onALLO(Allogene Therapeutics, Inc.)
- May 16, 2024— Set$5.00price target onFATE(Fate Therapeutics, Inc.)
- May 14, 2024— Set$13.00price target onFOLD(Amicus Therapeutics, Inc.)
- May 13, 2024— Set$4.00price target onMGNX(MacroGenics, Inc.)
- Feb 3, 2022— Set$170.00price target onALNY(Alnylam Pharmaceuticals, Inc.)
- Dec 1, 2021— Set$286.00price target onVRTX(Vertex Pharmaceuticals Incorporated)
- Nov 19, 2021— Set$120.00price target onBMRN(BioMarin Pharmaceutical Inc.)
Frequently Asked Questions
Who is Debjit Chattopadhyay?
Debjit Chattopadhyay is a stock analyst at Guggenheim covering 17 stocks primarily in Healthcare. They have issued 18 price targets since Nov 19, 2021.
What stocks does Debjit Chattopadhyay cover?
Debjit Chattopadhyay currently covers 17 stocks, including MAZE, PEPG, PHVS, KRYS, NTLA.
What is Debjit Chattopadhyay's latest price target?
Debjit Chattopadhyay's most recent price target was $7.00 on PEPG (PepGen Inc.), set on Feb 18, 2026.
What is Debjit Chattopadhyay's highest price target?
Debjit Chattopadhyay's highest issued price target is $286.00 on VRTX, set on Dec 1, 2021.
More Analysts at Guggenheim
Coverage based on publicly published price targets. Not investment advice.